Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157132 | 0.89 | HTR1A (0.50) | KCNH2ADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL1332649 | 0.86 | ADRA1D (0.60) | KCNH2ADRA1DADRA1AADRA1BMAOB | |
| SCHEMBL1332035 | 0.85 | ADRA1D (0.53) | KCNH2ADRA1DADRA1AADRA1BHTR1A | |
| Hydrochloric Acid SCHEMBL1333894 | 0.85 | ADRA1D (0.59) | KCNH2ADRA1DADRA1AADRA1BMAOB | |
| SCHEMBL1333250 | 0.82 | KCNH2 (0.71) | KCNH2SIGMAR1TMEM97DRD2HTR2A | |
| SCHEMBL1334361 | 0.82 | HTR1A (0.55) | KCNH2ADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL2157337 | 0.81 | KCNH2 (0.60) | KCNH2SIGMAR1TMEM97DRD2HTR2A | |
| SCHEMBL8642297 | 0.80 | TMEM97 (0.58) | HTR1ASLC6A4MAOBSIGMAR1TMEM97 | |
| SCHEMBL1332744 | 0.80 | KMT2A (0.60) | KCNH2ADRA1DADRA1AADRA1BMAOB | |
| SCHEMBL1334144 | 0.79 | DRD2 (0.69) | KCNH2SLC6A4SIGMAR1DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281890-A1 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION | 2011-11-17 | — | — | US | claimed |
| CN-101511187-B | Piperidine and piperazine derivatives | MS SCIENCE CORP | 2012-07-04 | — | — | CN | disclosed |
| US-8183374-B2 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183374-B2 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183374-B2 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20110281890-A1 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION | 2011-11-17 | — | — | US | disclosed |
| US-20110281890-A1 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION | 2011-11-17 | — | — | US | disclosed |
| US-20110281890-A1 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION | 2011-11-17 | — | — | US | disclosed |
| EP-1978959-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2011-11-09 | — | — | EP | disclosed |
| EP-1978959-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2011-11-09 | — | — | EP | disclosed |
| EP-2340835-A1 | Piperidine and piperazine derivatives | M's Science Corporation (JP) | 2011-07-06 | — | — | EP | disclosed |
| EP-1976525-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | AGY THERAPEUTICS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | AGY THERAPEUTICS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | AGY THERAPEUTICS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SUN CONNIE L | 2010-06-03 | — | — | US | disclosed |
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SUN CONNIE L | 2010-06-03 | — | — | US | disclosed |
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SUN CONNIE L | 2010-06-03 | — | — | US | disclosed |
| WO-2007089462-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES | M'S SCIENCE CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SIGMAR1, OPRM1, OPRD1 | KCNH2 332/4885ADRA1D 19/4885ADRA1A 18/4885 |
| US-20110281890-A1 | Piperidine and piperazine derivatives | SIGMAR1, OPRM1, OPRD1 | KCNH2 369/4885ADRA1D 50/4885ADRA1A 91/4885 |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | SIGMAR1, OPRM1, OPRD1 | KCNH2 360/4885ADRA1D 62/4885ADRA1A 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.